Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities.
Financial Results:
Alembic Pharmaceuticals Ltd reported Revenues for Q4FY25 of ₹1,770.00 Crores up from ₹1,517.00 Crore year on year, a rise of 16.68%.
Total Expenses for Q4FY25 of ₹1,592.00 Crores up from ₹1,337.00 Crores year on year, a rise of 19.07%.
Consolidated Net Profit of ₹157.00 Crores down 11.8% from ₹178.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹7.98, down 12.02% from ₹9.07 in the same quarter of the previous year.